Evommune

NASDAQ: EVMN ↗$15.05 USD~$200M (NASDAQ, post-listing) MCAP

#Chronic Spontaneous Urticaria #Atopic Dermatitis #Inflammatory Skin Diseases #IRAK4-driven Inflammation

Evommune is a US clinical-stage biotechnology company developing therapies for chronic inflammatory diseases. The company's pipeline is led by EVO101, an IRAK4 inhibitor in Phase 2 for chronic spontaneous urticaria and other inflammatory skin conditions, alongside additional earlier-stage programs. Evommune raised a $115M Series C to advance the pipeline.

Company Info

Sector:Biotechnology / Inflammation

Headquarters:Palo Alto, California, USA

Founded:2020

Website:www.evommune.com/

Upcoming Milestones & Key Dates

H2 2026

Clinical Trial

Continued Phase 2 readouts for EVO101 in chronic spontaneous urticaria

Q3 2026

Earnings

Q2 2026 earnings and pipeline update

Clinical Development Pipeline

EVO101

Target: IRAK4 inhibitor (degrader)

Chronic spontaneous urticaria (Phase 2 readout in 2026)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

EVO101

Target: IRAK4 inhibitor (degrader)

Atopic dermatitis and additional inflammatory skin indications

Preclinical

Phase 1

Phase 2

Phase 3

Approved

EVO301

Target: To be confirmed

Inflammatory disease (specific indication to be confirmed)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Evommune's lead drug fails in chronic hives, stock sinks ↗

Endpoints News reports that Evommune's lead clinical candidate failed to meet primary endpoints in chronic hives, sending shares down on the readout.

Leadership Team

Luis Peña

Chief Executive Officer

Careers & Job Openings

See all open roles

Multiple Departments

Palo Alto, CA

Apply Now →